• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mylan to cut 10% of workforce in restructuring efforts

December 7, 2016 By Sarah Faulkner

Mylan to cut 10% of workforce in restructuring effortsMylan (NSDQ:MYL) shares dropped 5% this morning after it said in regulatory filing that it expects to cut less than 10% of its global workforce as a result of its restructuring efforts.

The Canonsburg, Penn.-based company has about 35,000 employees, according to Reuters, and wrote in the SEC filing that it will implement restructuring programs in specific locations in an effort to take cost-cutting measures following a number of acquisitions that it made in the past year. Mylan said it will disclose more details, including how much the efforts will cost, as the company finalizes its plans.

Mylan has been under fire since August, after reports surfaced that it raised the price of its emergency epinephrine injector by 500% since it acquired the device from Merck (NYSE:MRK) nearly a decade ago. The company’s CEO, Heather Bresch, testified at a Congressional hearing and maintained that Mylan has spent a lot of money improving the device. Mylan is developing a generic that will be offered for $300, half the current price of the brand name product.

In October, Mylan said it would pay $465 million to settle claims that it underpaid U.S. government programs, including Medicaid, by classifying the device as a generic product and therefore paying significantly smaller rebates to state Medicaid programs. The government has not confirmed that the 2 groups have reached a settlement.

Drug pricing rose to the forefront of public discussion last year after Turing Pharmaceuticals raised the price of its malaria drug Daraprim from $13.50 to $750 a pill. President-elect Donald Trump weighed in on the issue in a Time magazine article published early this morning. “I’m going to bring down drug prices,” he said. “I don’t like what’s happened with drug prices.”

Filed Under: Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS